Skip to main content

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Objective

Background: Many cutting-edge therapies rely on manipulating the adaptive immune system, which has evolved a vast diversity (repertoire) of immune receptors to recognize and remove pathogens and cancer cells. The sequence-data sets characterizing this Adaptive Immune Receptor Repertoire (i.e., AIRR-seq data) have the potential to revolutionize vaccine research and the development of therapies against autoimmune diseases and cancer; however, AIRR-seq data are typically stored and curated by individual labs, using a variety of tools and technologies. Sharing these data in a common way across disease studies, labs, and institutions around the world will improve our ability to recognize patterns in basic research and clinical trials, and increase our confidence in these patterns. The existing iReceptor Platform uses community-developed standards to facilitate sharing of AIRR-seq data by enabling queries across a system of distributed data repositories.

Project: The iReceptor Plus consortium of researchers from Europe and Canada will address several key challenges to optimally sharing AIRR-seq data among public and industrial partners: protecting patient privacy and the intellectual property of partners, performing complex analyses on data brought together from many sources, and expanding the size and number of repositories that can be integrated in the network.

Impact: The iReceptor Plus project will facilitate sharing of AIRR-seq data among multiple institutions, including biopharmaceutical companies and researchers working with human confidential data, across multiple diseases, treatments and populations. This will lead to a better understanding of the causes of infectious and autoimmune diseases and cancer, which can lead to early detection and suggest novel therapies. These improvements will reduce the social and economic burden of these diseases, advance Europe and Canada’s leadership role in immunotherapy, and contribute to improved patient care worldwide

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-SC1-2018-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

BAR ILAN UNIVERSITY
Address
Bar Ilan University Campus
52900 Ramat Gan
Israel
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 975 750

Participants (19)

Simon Fraser University
Canada
EU contribution
€ 0
Address
University Drive 8888
V5A 1S6 Burnaby
Activity type
Higher or Secondary Education Establishments
SORBONNE UNIVERSITE
France
EU contribution
€ 647 000
Address
21 Rue De L'ecole De Medecine
75006 Paris
Activity type
Higher or Secondary Education Establishments
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Canada
EU contribution
€ 0
Address
Kings College Circle 27
M5S 1A1 Toronto
Activity type
Higher or Secondary Education Establishments
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Germany
EU contribution
€ 649 750
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Activity type
Research Organisations
ACONDICIONAMIENTO TARRASENSE ASSOCIACION
Spain
EU contribution
€ 280 625
Address
Carrer De La Innovacio 2
08225 Terrassa
Activity type
Research Organisations
INESC TEC - INSTITUTO DE ENGENHARIADE SISTEMAS E COMPUTADORES, TECNOLOGIA E CIENCIA
Portugal
EU contribution
€ 877 292,50
Address
Rua Dr Roberto Frias Campus Da Feup
4200 465 Porto
Activity type
Research Organisations
UNIVERSITY OF HAIFA
Israel
EU contribution
€ 499 375
Address
Abba Khushy Blvd Mount Carmel
31905 Haifa
Activity type
Higher or Secondary Education Establishments
UNIVERSITETET I OSLO
Norway
EU contribution
€ 360 000
Address
Problemveien 5-7
0313 Oslo
Activity type
Higher or Secondary Education Establishments
MITMYNID LDA
Portugal
EU contribution
€ 301 250
Address
Travessa Das Murtas 68
4600 109 Amarante
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASCORA GMBH
Germany
EU contribution
€ 508 750
Address
Birkenallee 43
27777 Ganderkesee
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MEDGENOME INC
United States
EU contribution
€ 150 250
Address
348 Hatch Drive
94404 Foster City
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INFINIDAT LTD
Israel
EU contribution
€ 386 750
Address
9 Hamenofim St.
46725 Herziliya
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
10X GENOMICS, INC.
United States
EU contribution
€ 150 250
Address
7068 Koll Center Parkway, Ste 401
94566 Pleasanton
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CLALIT HEALTH SERVICES
Israel
EU contribution
€ 167 500
Address
Arlozorov Street 101
62098 Tel Aviv
Activity type
Research Organisations
THE UNIVERSITY OF TEXAS SYSTEM
United States
EU contribution
€ 679 800
Address
Colorado Street 601
78701 2982 Austin
Activity type
Higher or Secondary Education Establishments
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 556 875
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
OSLO UNIVERSITETSSYKEHUS HF

Participation ended

Norway
EU contribution
€ 0
Address
Kirkeveien 166 Tarnbygget
0450 Oslo
Activity type
Higher or Secondary Education Establishments
TIME.LEX
Belgium
EU contribution
€ 265 000
Address
Joseph Stevensstraat 7
1000 Brussel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INTERTEAM LTD
Israel
EU contribution
€ 400 707,50
Address
Ahad Haam Street 16
92103 Jerusalem
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)